Literature DB >> 9445303

5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension.

L Wright1, R M Tuder, J Wang, C D Cool, R A Lepley, N F Voelkel.   

Abstract

Inflammatory infiltrates and endothelial cell proliferation have been appreciated in plexiform and concentric lesions, which characterize the vascular remodeling in primary pulmonary hypertension (PPH). Leukotriene production by perivascular and alveolar macrophages relies on activation of 5-lipoxygenase (5-LO), with translocation of the enzyme to the nuclear membrane, and association with the 5-LO activating protein (FLAP). Using immunohistochemical staining, we localized and semi-quantitatively estimated the abundance of 5-LO and FLAP in lungs obtained from patients with PPH, patients with interstitial lung disease (ILD), and normal control subjects. Expression of 5-LO and FLAP was prominent in alveolar macrophages in both the normal and PPH lungs; however, alveolar macrophages were more frequently clustered in the vicinity of remodeled blood vessel in PPH. Medium- and small-size pulmonary arteries in PPH showed more abundant FLAP expression than in control and ILD lungs. 5-LO expression in small arteries in PPH was more intense than in control and ILD patients. Endothelial cells in plexiform and concentric lesions in PPH expressed both 5-LO and FLAP. In situ hybridization confirmed the presence of 5-LO transcripts in macrophages and endothelial cells of the remodeled vessels in PPH. We propose that the overexpression of 5-LO and FLAP represents evidence for the participation of inflammation in the process of PPH vasculopathy or, alternatively, that the overabundance of the enzymes involved in generation of inflammatory mediators may themselves be related to vascular cell proliferation and cell growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445303     DOI: 10.1164/ajrccm.157.1.9704003

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

1.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.

Authors:  C D Cool; J S Stewart; P Werahera; G J Miller; R L Williams; N F Voelkel; R M Tuder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 2.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

3.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

4.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

5.  Biosynthesis of proresolving lipid mediators by vascular cells and tissues.

Authors:  Anuran Chatterjee; Sevan Komshian; Brian E Sansbury; Bian Wu; Giorgio Mottola; Mian Chen; Matthew Spite; Michael S Conte
Journal:  FASEB J       Date:  2017-04-25       Impact factor: 5.191

6.  Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.

Authors:  Wen Tian; Xinguo Jiang; Yon K Sung; Eric Shuffle; Ting-Hsuan Wu; Peter N Kao; Allen B Tu; Peter Dorfmüller; Aiqin Cao; Lingli Wang; Gongyong Peng; Yesl Kim; Patrick Zhang; James Chappell; Shravani Pasupneti; Petra Dahms; Peter Maguire; Hassan Chaib; Roham Zamanian; Marc Peters-Golden; Michael P Snyder; Norbert F Voelkel; Marc Humbert; Marlene Rabinovitch; Mark R Nicolls
Journal:  Circulation       Date:  2019-08-29       Impact factor: 29.690

7.  Placenta growth factor-induced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1alpha (HIF-1alpha) in endothelial cells.

Authors:  Nitin Patel; Vijay K Kalra
Journal:  J Biol Chem       Date:  2010-05-06       Impact factor: 5.157

8.  Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension.

Authors:  Angela Ghatnekar; Izabela Chrobak; Charlie Reese; Lukasz Stawski; Francesca Seta; Elaine Wirrig; Jesus Paez-Cortez; Margaret Markiewicz; Yoshihide Asano; Russell Harley; Richard Silver; Carol Feghali-Bostwick; Maria Trojanowska
Journal:  Am J Pathol       Date:  2013-04-11       Impact factor: 4.307

Review 9.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

Review 10.  Leukotrienes in pulmonary arterial hypertension.

Authors:  Wen Tian; Xinguo Jiang; Yon K Sung; Jin Qian; Ke Yuan; Mark R Nicolls
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.